Announcements Trials
Browse Landscape

Phase

Phase 1/2 6Phase 1 6Phase 2 4Phase 3 2Phase 4 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 43Leukemia 7Myelodysplastic Syndromes 4Leukemia, Myelomonocytic, Chronic 4Recurrence 2Pathologic Complete Response 2Neoplasms 2MDS 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myeloid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Higher-risk Myelodysplastic Syndrome 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Pemetrexed 9Epoetin Alfa 9venetoclax 8Prednisone 8Fentanyl 8Drug Therapy 8Doxorubicin 8atezolizumab 7Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × Azacitidine × Clear all
NCT04161885 2025-10-06

VIALE-T

AbbVie

Phase 3 Terminated
465 enrolled
Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT03941964 2023-03-20

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

AbbVie

Phase 3 Completed
60 enrolled 12 charts
Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡